Seeking Alpha
01 Aug 2026, 18:12 UTC · 1h ago
Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
01 Aug 2026, 18:12 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Collegium's 2026 guidance projects revenue of $865–895M and adjusted EBITDA of $475–500M with a 55% margin. — Concrete financial targets and high margins provide a clear valuation benchmark for investors.
+0.60The AZSTARYS acquisition is expected to generate $60–70M in revenue by 2026 and over $50M in annual synergies within a year. — Direct revenue growth and cost efficiencies from the acquisition improve the company's growth profile.
+0.50Collegium is transitioning its business model from a pain-management roll-up to a Central Nervous System (CNS) platform. — Diversification into the ADHD market reduces reliance on a single therapeutic area and expands the total addressable market.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
The company is utilizing $300M in debt and $350M in cash to fund the AZSTARYS acquisition. — Increased leverage introduces financial risk, though offset by the strategic nature of the acquisition.
-0.20Which stocks this story touches
The company is expanding its platform via acquisition with strong 2026 revenue and EBITDA guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Proactive Investors
4h ago
